vs
Side-by-side financial comparison of Can-Fite BioPharma Ltd. (CANF) and Rafael Holdings, Inc. (RFL). Click either name above to swap in a different company.
Rafael Holdings, Inc. is the larger business by last-quarter revenue ($240.0K vs $202.0K, roughly 1.2× Can-Fite BioPharma Ltd.). Can-Fite BioPharma Ltd. runs the higher net margin — -2413.9% vs -4090.0%, a 1676.1% gap on every dollar of revenue. On growth, Rafael Holdings, Inc. posted the faster year-over-year revenue change (87.5% vs -36.1%).
Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on developing proprietary small molecule therapeutics targeting adenosine receptors. Its product pipeline addresses unmet medical needs across oncology, inflammatory diseases, and liver disorders, with operations serving global healthcare markets and research partnership networks worldwide.
Rafael Advanced Defense Systems Ltd. is an Israeli defense technology company. It was founded as Israel's National R&D Defense Laboratory for the development of weapons and military technology within the Israeli Ministry of Defense; in 2002 it was incorporated as a limited company.
CANF vs RFL — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $202.0K | $240.0K |
| Net Profit | $-4.9M | $-9.8M |
| Gross Margin | — | — |
| Operating Margin | -2424.8% | -4225.4% |
| Net Margin | -2413.9% | -4090.0% |
| Revenue YoY | -36.1% | 87.5% |
| Net Profit YoY | -23.2% | -9.0% |
| EPS (diluted) | $0.00 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $240.0K | ||
| Q2 25 | $202.0K | — | ||
| Q3 24 | — | $165.0K | ||
| Q2 24 | $316.0K | $336.0K | ||
| Q1 24 | — | $68.0K | ||
| Q4 23 | — | $68.0K | ||
| Q3 23 | — | $68.0K | ||
| Q2 23 | — | $71.0K |
| Q4 25 | — | $-9.8M | ||
| Q2 25 | $-4.9M | — | ||
| Q3 24 | — | $-4.5M | ||
| Q2 24 | $-4.0M | $-32.4M | ||
| Q1 24 | — | $6.0M | ||
| Q4 23 | — | $-3.6M | ||
| Q3 23 | — | $1.2M | ||
| Q2 23 | — | $-1.4M |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 74.7% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | -4225.4% | ||
| Q2 25 | -2424.8% | — | ||
| Q3 24 | — | -2330.3% | ||
| Q2 24 | -1295.6% | -27726.5% | ||
| Q1 24 | — | -4622.1% | ||
| Q4 23 | — | -3644.1% | ||
| Q3 23 | — | -3839.7% | ||
| Q2 23 | — | -4269.0% |
| Q4 25 | — | -4090.0% | ||
| Q2 25 | -2413.9% | — | ||
| Q3 24 | — | -2707.9% | ||
| Q2 24 | -1252.2% | -9628.3% | ||
| Q1 24 | — | 8892.6% | ||
| Q4 23 | — | -5350.0% | ||
| Q3 23 | — | 1792.6% | ||
| Q2 23 | — | -2023.9% |
| Q4 25 | — | $-0.19 | ||
| Q2 25 | $0.00 | — | ||
| Q3 24 | — | $-0.19 | ||
| Q2 24 | $0.00 | $-1.36 | ||
| Q1 24 | — | $0.25 | ||
| Q4 23 | — | $-0.15 | ||
| Q3 23 | — | $0.05 | ||
| Q2 23 | — | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.5M | $45.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.2M | $85.2M |
| Total Assets | $7.7M | $105.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.5M | ||
| Q2 25 | $6.5M | — | ||
| Q3 24 | — | $2.7M | ||
| Q2 24 | $4.7M | $7.4M | ||
| Q1 24 | — | $7.1M | ||
| Q4 23 | — | $13.2M | ||
| Q3 23 | — | $21.5M | ||
| Q2 23 | — | $15.4M |
| Q4 25 | — | $85.2M | ||
| Q2 25 | $4.2M | — | ||
| Q3 24 | — | $82.2M | ||
| Q2 24 | $2.5M | $86.1M | ||
| Q1 24 | — | $104.9M | ||
| Q4 23 | — | $98.2M | ||
| Q3 23 | — | $100.3M | ||
| Q2 23 | — | $98.5M |
| Q4 25 | — | $105.4M | ||
| Q2 25 | $7.7M | — | ||
| Q3 24 | — | $96.8M | ||
| Q2 24 | $5.9M | $101.6M | ||
| Q1 24 | — | $106.1M | ||
| Q4 23 | — | $95.5M | ||
| Q3 23 | — | $98.8M | ||
| Q2 23 | — | $96.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.8M | $-6.8M |
| Free Cash FlowOCF − Capex | $-4.8M | — |
| FCF MarginFCF / Revenue | -2353.0% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-6.8M | ||
| Q2 25 | $-4.8M | — | ||
| Q3 24 | — | $-2.9M | ||
| Q2 24 | $-4.0M | $-251.0K | ||
| Q1 24 | — | $-2.5M | ||
| Q4 23 | — | $-2.1M | ||
| Q3 23 | — | $-1.4M | ||
| Q2 23 | — | $-1.3M |
| Q4 25 | — | — | ||
| Q2 25 | $-4.8M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-4.0M | $-375.0K | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | -2353.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1278.5% | -111.6% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | 0.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.3% | 36.9% | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.42× | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1.19× | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
